Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) saw a significant decrease in short interest in May. As of May 29th, there was short interest totaling 50 shares, a decrease of 99.8% from the May 14th total of 23,016 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 1,489 shares, the days-to-cover ratio is currently 0.0 days.
Innate Pharma Stock Performance
Innate Pharma stock remained flat at $1.65 during mid-day trading on Tuesday. The firm has a 50 day moving average price of $1.64 and a two-hundred day moving average price of $1.92. Innate Pharma has a 1-year low of $1.37 and a 1-year high of $2.25.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Featured Stories
- Five stocks we like better than Innate Pharma
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
